{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:41:02Z","timestamp":1780105262854,"version":"3.54.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13555-025-01346-w","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:19:13Z","timestamp":1743362353000},"page":"1093-1111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R.","family":"Ingram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Ciaravino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rolleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Pelligra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linnea","family":"Thorlacius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1346_CR1","first-page":"184","volume":"231","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Del Marmol V, Mrowietz U, et al. Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment. Classif Dis Eval Dermatol. 2015;231:184\u201390.","journal-title":"Classif Dis Eval Dermatol"},{"key":"1346_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18.","journal-title":"Nat Rev Dis Primers"},{"key":"1346_CR3","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"\u0141 Matusiak","year":"2020","unstructured":"Matusiak \u0141. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183:e171\u20137.","journal-title":"Br J Dermatol"},{"key":"1346_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project. J Am Acad Dermatol. 2020;82:366\u201376.","journal-title":"J Am Acad Dermatol"},{"key":"1346_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","volume":"21","author":"ZS Patel","year":"2017","unstructured":"Patel ZS, Hoffman LK, Buse DC, et al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017;21:49.","journal-title":"Curr Pain Headache Rep"},{"key":"1346_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jaad.2020.05.090","volume":"83","author":"S Wright","year":"2020","unstructured":"Wright S, Strunk A, Garg A. New-onset depression among children, adolescents, and adults with hidradenitis suppurativa. J Am Acad Dermatol. 2020;83:1360\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"1346_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaad.2021.06.843","volume":"86","author":"S Wright","year":"2022","unstructured":"Wright S, Strunk A, Garg A. Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa. J Am Acad Dermatol. 2022;86:55\u201360.","journal-title":"J Am Acad Dermatol"},{"key":"1346_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bjd\/ljac018","volume":"188","author":"LAV Orenstein","year":"2023","unstructured":"Orenstein LAV, Salame N, Siira MR, et al. Pain experiences among those living with hidradenitis suppurativa: a qualitative study. Br J Dermatol. 2023;188:41\u201351.","journal-title":"Br J Dermatol"},{"key":"1346_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000502139","volume":"236","author":"A Molina-Leyva","year":"2020","unstructured":"Molina-Leyva A, Cuenca-Barrales C. Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology. 2020;236:59\u201365.","journal-title":"Dermatology"},{"key":"1346_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179:642\u201350.","journal-title":"Br J Dermatol"},{"key":"1346_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan G. Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1346_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000534463","volume":"240","author":"JR Ingram","year":"2024","unstructured":"Ingram JR, Ciaravino V, Rolleri R, et al. Electronic patient-reported outcomes in hidradenitis suppurativa: content validity and usability of the electronic hidradenitis suppurativa symptom daily diary, hidradenitis suppurativa symptom questionnaire, and hidradenitis suppurativa quality of life questionnaire. Dermatology. 2024;240:65\u201376.","journal-title":"Dermatology"},{"key":"1346_CR13","unstructured":"US Food and Drug Administration. Patient-focused drug development: Methods to identify what is important to patients. Volume 2023."},{"key":"1346_CR14","unstructured":"US Food and Drug Administration. Patient-focused drug development: Guidance 4\u2014incorporating clinical outcome assessment into endpoint for regulatory decision making. Volume 2023."},{"key":"1346_CR15","unstructured":"US Food and Drug Administration. Patient-reported outcome measures: Use in medical product development to support labeling claims. Volume 2023."},{"key":"1346_CR16","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD I). https:\/\/clinicaltrials.gov\/NCT04242446. Accessed 12 Feb 2025."},{"key":"1346_CR17","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD II). https:\/\/clinicaltrials.gov\/NCT04242498. Accessed 12 Feb 2025."},{"key":"1346_CR18","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403:2504\u201319.","journal-title":"Lancet"},{"key":"1346_CR19","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"J Kirby","year":"2020","unstructured":"Kirby J, Thorlacius L, Villumsen B, et al. The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183:340\u20138.","journal-title":"Br J Dermatol"},{"key":"1346_CR20","unstructured":"Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5th ed: Houghton Mifflin. 2003."},{"key":"1346_CR21","unstructured":"Centers for Disease Control and Prevention (CDC). Defining adult overweight & obesity. Volume 2023."},{"key":"1346_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1081\/COPD-200050663","volume":"2","author":"RD Hays","year":"2005","unstructured":"Hays RD, Farivar SS, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD. 2005;2:63\u20137.","journal-title":"COPD"},{"key":"1346_CR23","doi-asserted-by":"crossref","unstructured":"Cappelleri JC, Zou KH, Bushmakin AG, et al. Patient-reported outcomes measurement, implementation and interpretation: Chapman and Hall\/CRC. 2014.","DOI":"10.1201\/b16139"},{"key":"1346_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","volume":"157","author":"JS Barbieri","year":"2021","unstructured":"Barbieri JS, Gelfand JM. Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis. JAMA Dermatol. 2021;157:1236\u20137.","journal-title":"JAMA Dermatol"},{"key":"1346_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/ijerph19053140","volume":"19","author":"W Bily","year":"2022","unstructured":"Bily W, Jauker J, Nics H, et al. Associations between patient-reported and clinician-reported outcome measures in patients after traumatic injuries of the lower limb. Int J Environ Res Public Health. 2022;19:8.","journal-title":"Int J Environ Res Public Health"},{"key":"1346_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamadermatol.2023.2008","volume":"159","author":"V Long","year":"2023","unstructured":"Long V, Chen Z, Du R, et al. Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling. JAMA Dermatol. 2023;159:811\u20139.","journal-title":"JAMA Dermatol"},{"key":"1346_CR27","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","volume":"36","author":"C Xiao","year":"2013","unstructured":"Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 2013;36:E1\u201316.","journal-title":"Cancer Nurs"},{"key":"1346_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/jamadermatol.2023.3282","volume":"159","author":"N Mastacouris","year":"2023","unstructured":"Mastacouris N, Tannenbaum R, Strunk A, et al. Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice: a historic consensus statement. JAMA Dermatol. 2023;159:1258\u201366.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01346-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01346-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T17:29:42Z","timestamp":1745688582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01346-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01346-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John R Ingram: Receives a stipend as Editor\u2011in\u2011Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate; consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, MoonLake, Novartis, UCB, and Union Therapeutics, and has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio; co\u2011copyright holder of HiSQOL\u00a9, patient global assessment, and HS-IGA; his department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. J\u00e9r\u00e9my Lambert, Valerie Ciaravino, Robert Rolleri, Ingrid Pansar, Luke Peterson: Employees and shareholders of UCB. Christopher G Pelligra: Employee of Evidera, a part of ThermoFisher Scientific that receives funding for research from UCB. Linnea Thorlacius: Received speaker honoraria from UCB and is co\u2011copyright holder of HiSQOL\u00a9 and HS-IGA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study protocol, amendments, and patient informed consent were reviewed by a national, regional, or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}